Bicara Therapeutics (BCAX) Stock: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$17.63
-0.57 (-3.13%)
▼
5d:
-8.22%
30d:
-25.17%
90d:
-39.66%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $17.63, which is considered oversold relative to its 30-day fair value range of $19.90 to $24.14.
Technical Outlook: Technically, BCAX is showing sideways momentum. The price is currently testing key support at $17.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $35.50 (+101.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAX is showing sideways momentum. The price is currently testing key support at $17.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $35.50 (+101.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.90 -
$24.14
Company Quality Score
50/100
(HOLD)
Options IV Signal
100th percentile
(ELEVATED)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 101.4% below Wall St target ($35.50)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.90 -
$24.14
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.87
(16.3%)
Support & Resistance Levels
Support Level
$17.56
Resistance Level
$23.34
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.01
Wall Street Target
$35.50
(+101.4%)
Share & Embed Analysis
Last updated: October 03, 2026 1:38 PM ET
Data refreshes hourly during market hours. Next update: 2:38 PM
Data refreshes hourly during market hours. Next update: 2:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ivan Hyep
SELL
9200 shares
2026-04-21
Claire Mazumdar
SELL
15000 shares
2026-04-20
Ryan Cohlhepp
SELL
12500 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
